In December 2017, INOVIO and ApolloBio entered a license and collaboration agreement providing ApolloBio with the right to develop, manufacture, and commercialize VGX-3100, our DNA vaccine product candidate designed to treat pre-cancers caused by HPV, within the territories of China, Hong Kong, Macao and Taiwan.

In December 2020, INOVIO and a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University received a $37.6 million grant from the U.S. Defense Advanced Research Projects Agency (DARPA), a research and development agency of the U.S. Department of Defense (DoD) and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), to use INOVIO’s DNA-encoded monoclonal antibody (dMAb®) technology to develop anti-SARS-CoV-2-specific dMAbs which could offer versatile capabilities to function as both a therapeutic and preventive treatment for COVID-19. As part of DARPA’s two-year grant, INOVIO and Wistar teams will construct COVID-19 dMAb candidates mirroring AstraZeneca’s traditional recombinant monoclonal antibody candidates currently being tested in clinical trials to treat COVID-19.

INOVIO and Advaccine are partnering to advance the development of COVID-19 DNA vaccine INO-4800 in a global Phase 2/3 clinical trial.

In August 2016, INOVIO incorporated a subsidiary, Geneos Therapeutics, Inc., to develop and commercialize neoantigen-based personalized cancer therapies. While we leverage our precisely designed plasmids (SynCon®) and CELLECTRA® delivery technologies to break tolerance and create cancer products targeting shared tumor specific antigens, Geneos is focusing exclusively on leveraging our technology platform to advance the field of patient-specific neoantigen therapies for cancer. We believe that our clinically validated DNA medicines technology platform is well suited for advancing individualized therapies due to its rapid product design and manufacturing benefits, ability to combine multiple neoantigens into formulations, and generation of potent killer T cell responses that are needed to drive clinical efficacy. We have licensed our SynCon and CELLECTRA technology platform to Geneos to be used in the field of personalized, neoantigen based therapy for cancer.

In May 2019, INOVIO and Plumbline Life Sciences established an animal health collaboration to develop a novel vaccine against the African Swine Fever virus.

In May 2017, INOVIO entered into a clinical study and supply agreement with Regeneron to provide its PD-1 inhibitor, REGN2810, for use in our clinical trials evaluating INO-5401 and INO-9012, in combination with REGN2810, in patients with newly diagnosed glioblastoma multiforme (GBM). Under the terms of the agreement, INOVIO will conduct and fund the trial based upon a mutually agreed upon study design.